Table of Contents
•Primary interviews were conducted with key industry experts and regulatory authorities. Designations of interviewed participants include chief executive officers, marketing managers, directors, and vice-presidents.
•Secondary research sources such as in-house Frost & Sullivan database, Frost & Sullivan’s Decision Support Database, company annual reports, scientific journals, and industry-related articles have been utilized.
•The objective of the research service is to present a comprehensive analysis of the European Percutaneous Coronary Interventions market with respect to market potential and key market dynamics.
•The study also covers factors driving growth, challenges affecting the industry, and opportunities within the total market and the market segments as estimated for the forecast period.
•The study period covered is from 2010 to 2018, with the base year as 2013 and forecast period from 2014 to 2018.
•The western European Percutaneous Coronary Intervention (PCI) Devices market, comprising coronary stents, catheters, percutaneous transluminal coronary angioplasty (PTCA) balloons (plain and drug-eluting balloons), guidewires, introducers, and embolic protection devices (EPDs), was estimated at $ x million in 2013.
•It is a mature market and is expected to grow at a CAGR of x % and reach $ x million by 2018. Most western European governments have incorporated the prevention and treatment of cardiovascular diseases (CVDs) within healthcare provisions, with Germany being the largest contributor in terms of revenue in this market.
•While the number of coronary stenting procedures performed in western Europe is expected to grow steadily due to better reimbursement and increased diagnosis and awareness, the selling price of stents is declining significantly with intensified competition, product bundling, and budgetary pressure in hospitals. This has led to a decline in the overall coronary stents segment.
•However, an exception to the coronary stenting segment decline will be bioabsorbable stents (BAS), which are likely to be adopted over this period due to prevention of stent thrombosis found in drug-eluting stents (DES), and thus limit the slide in market value.
•The number of PCI procedures performed in western Europe, especially in Spain and Italy, is expected to rise as a result of increased treatment of more complex cases. However, the declining Average Selling Price (ASP) across almost every PCI product segment will neutralize the increase in revenue.
•Moreover, lack of reimbursement in countries like Spain, for advanced technologies like EPD, has hindered the adoption of these devices, despite the potential clinical benefits derived from their usage.
Key Questions this Study will Answer
What is the market size and potential for PCI products?
Which segment of PCI is growing the fastest? How long will it continue to grow, and at what rate?
What is the greatest challenge faced by the PCI devices market and how can it be overcome?
Which are the major countries, and what are the important trends for each segment in PCI?
Focus will be on innovations like bioabsorbable stents and drug-eluting bioabsorbable stents that are completely absorbed by the body without compromising the integrity of the vessel.
For multinational corporations, product portfolio expansion through acquisition of smaller companies with innovative PCI products is the best way to increase topline in this mature market.
Exploring novel technology in a niche sector is the ideal way to build brand value for new entrants.
Key Companies to Watch
•Boston Scientific is the largest supplier of percutaneous coronary intervention devices to the western European market.
•Being a large organization, it has access to considerable research and development and marketing resources.
•Its recent acquisition of Bridgepoint Medical is helping the company provide novel solutions for treating Coronary Chronic Total Occlusions (CTOs).
•Medtronic is equally active and is giving tough competition to Boston Scientific in the PCI space.
•It has direct sales offices located extensively throughout Europe.
•Its launch of Export Advance aspiration catheter in 2013 for thrombus removal is expected to have a big impact on the company’s revenue.
•Abbott Laboratories has dedicated physician training programmes which train and evaluate physicians, nurses, and other technicians regarding the efficient usage of their devices.
•Its product and service diversity, along with strong sales and distributor networks, enables it to reach end users effectively.
•Introduction of Absorb Bioresorbable Vascular Scaffold System is expected to further increase its foothold.
3 Big Predictions
Innovations and usage of bioabsorbable stents and drug-eluting bioabsorbable stents will hold the key to market revenue for stents segment.
Increased brand loyalty through better relationship with end users and a more effective after-sales service will help companies sustain in the mature PCI market.
Creating awareness among end users and surgeons and research in new percutaneous coronary interventional products will facilitate adoption of new products.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Global Biodegradable Stents Market: Overview Biodegradable Stents are the third generation of stents used in the treatment of coronary artery diseases, which are completely absorbed in the body after the ...
The global coronary stent market is expected to reach USD 10.31 billion by 2021 from USD 7.16 billion in 2016, at a CAGR of 7.6% from 2016 to 2021 Major factors contributing to the growth of the global ...
India Non-Vascular Stents Market Outlook to 2023 Summary GlobalData’s new report, India Non-Vascular Stents Market Outlook to 2023, provides key market data on the India Non-Vascular Stents market. The ...